Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Oncol Rep. 2011 Feb 24;25(5):1329–1335. doi: 10.3892/or.2011.1195

Figure 1.

Figure 1

TGF-β1 promotes glioblastoma cells migration and invasion. (A) T98G cells were treated with the various doses of human recombinant TGF-β1 (invitrogen). Cell viability was measured after treatment for 24 h by MTT assay. (B) and (C) Confluent T98G glioblastoma cell monoplayers were scratched with a pipette tip and then treated with TGF-β1 (1ng/ml) in the presence or absence of SB (Sigma-aldrich, St. Louis, MO) (10nmol/ml) for 24 h. Cell migration to the wound area was then examined by light microscope for 24h post-scratch. (D) The percentage of total area covered by cells was assessed with MCID software. #P<0.05 and *P<0.01, compared with control group. (E) T98G glioma cells were seeded onto the upper BD BioCoat matrigel invasion chamber in serum-free medium containing TGF-β1 (1ng/ml) in the presence or absence of SB (10nmol/ml). After 24 h of incubation, cells on the lower surface of the membrane were stained with CellTracker Green (Molecular Probes, Eugene, OR), and (F) 9 different areas of invaded cells were counted by a fluorescent microscope. *P<0.01, compared with control group.